-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30

Benzinga·09/01/2026 12:29:20
Listen to the news
Guggenheim analyst Michael Schmidt initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy rating and announces Price Target of $30.